SCHEMBL19625609

SCHEMBL19625609

C=CCNC1=C(NS(=O)(=O)c2ccc(C)cc2)C(=O)c2ccccc2C1=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.53
▸ KMT2A Q03164 4/20 0.53
▸ ALDH1A1 P00352 3/20 0.53
▸ NSD2 O96028 3/20 0.53
▸ MITF O75030 2/20 0.53
▸ L3MBTL1 Q9Y468 2/20 0.53
▸ CASP3 P42574 1/20 0.53
▸ HTT P42858 1/20 0.53
▸ SENP8 Q96LD8 1/20 0.53
▸ SENP7 Q9BQF6 1/20 0.53
▸ SENP6 Q9GZR1 1/20 0.53
▸ NAT1 P18440 3/20 0.51
▸ MAPT P10636 4/20 0.50
▸ USP2 O75604 1/20 0.50
▸ POLB P06746 1/20 0.50
▸ CYP2C9 P11712 1/20 0.50
▸ CYP2C19 P33261 1/20 0.50
▸ NOD2 Q9HC29 1/20 0.50
▸ PTPRC P08575 1/20 0.49
▸ MEN1 O00255 3/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16296966 0.87 NAT1 (0.59) LMNAKMT2AALDH1A1NSD2MITF
SCHEMBL16297128 0.80 LMNA (0.77) LMNAKMT2AALDH1A1NSD2MITF
SCHEMBL16296994 0.77 ALDH1A1 (0.60) LMNAKMT2AALDH1A1NSD2MITF
SCHEMBL19628263 0.76 ALDH1A1 (0.67) LMNAKMT2AALDH1A1NSD2MITF
SCHEMBL19625588 0.75 MAPT (0.68) LMNAKMT2AALDH1A1NSD2MITF
SCHEMBL3498087 0.74 MEN1 (0.74) LMNAKMT2AALDH1A1MAPTPOLB
SCHEMBL16297214 0.72 KMT2A (0.65) LMNAKMT2AALDH1A1NSD2MITF
SCHEMBL561968 0.71 NPSR1 (0.62) KMT2AALDH1A1L3MBTL1MEN1GAA
SCHEMBL7952246 0.70 ALDH1A1 (0.58) LMNAKMT2AALDH1A1NSD2MITF
SCHEMBL16296919 0.70 LMNA (1.00) LMNAKMT2AALDH1A1NSD2MITF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170334842-A1 INHIBITORS OF THE MITF MOLECULAR PATHWAY UNIVERSITY OF KANSAS 2017-11-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170334842-A1 INHIBITORS OF THE MITF MOLECULAR PATHWAY MITF, TFEB, TYR LMNA 3726/4885KMT2A 2146/4885ALDH1A1 2444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback